This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
by Zacks Equity Research
Gilead (GILD) and partner Arcus Biosciences (RCUS) present data from metastatic colorectal cancer and gastrointestinal cancer study.
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 94.85% and 454.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Arcus Biosciences, Inc. (RCUS) Could Surge 151.61%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 151.6% in Arcus Biosciences, Inc. (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.
Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
by Zacks Equity Research
Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.
Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress
by Zacks Equity Research
Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
by Zacks Equity Research
Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
by Zacks Equity Research
Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
by Zacks Equity Research
Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Adaptive Biotechnologies (ADPT): Can Its 9.5% Jump Turn into More Strength?
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak
by Zacks Equity Research
Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.
Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study
by Zacks Equity Research
Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -4% and 19.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -11.96% and 62%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 10.17% and 38.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 10% and 3.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study
by Zacks Equity Research
Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.
Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases
by Zacks Equity Research
Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.
Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates
by Zacks Equity Research
Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.
TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines
by Zacks Equity Research
TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow
by Zacks Equity Research
Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.